The electronic quality management system (eQMS) supports Acrosian’s continued growth and commitment to building quality into its operations from the start 

PRINCETON, N.J. (September 23, 2026) — Acrosian, the AI-augmented biometrics CRO providing integrated clinical data management, biostatistics, statistical programming, and medical writing services, today announced a new partnership with ZenQMS to implement its electronic quality management system (eQMS) as Acrosian continues to expand its operations and client work.

The investment represents another step in Acrosian’s growth following the company’s launch in July 2026. Acrosian is building its operating model around a unified quality system designed to support its biometrics services and the AI-augmented capabilities being progressively built across the organization.

ZenQMS provides electronic quality management software purpose-built for life sciences and GxP-regulated organizations. Acrosian will use the platform to support key quality processes and provide the scalable quality foundation needed as the company grows.

“Quality has been part of the Acrosian operating model from day one, and selecting the right eQMS is an important early decision for us,” said Aparna (Tanya) Chowdhury, CISA, CDPSE, Chief Audit and Compliance Officer at Acrosian. “We wanted a system designed that could support how we operate today and grow with us. ZenQMS gives us that foundation and helps ensure our quality processes remain consistent, traceable, and ready to support the expectations of global sponsors and clients.”

The ZenQMS platform supports document management, training, quality events, change control, audits, and other quality processes within a centralized system. The platform is validated for GxP use and supports requirements including 21 CFR Part 11 and EU Annex 11.

For Acrosian, the implementation is part of a broader strategy to establish the systems and processes needed to support long-term growth without having to retrofit quality infrastructure later.

“We have been very deliberate about how we are building Acrosian,” said Soumitra Chowdhury, MBA, Co-founder and Chief Executive Officer of Acrosian. “As our client base and team grow, the systems behind our work need to grow with us. This partnership is one of the many important investments in building the kind of biometrics CRO that we believe sponsors are looking for.”

Acrosian’s approach places quality governance at the executive level, led by Tanya Chowdhury as Chief Audit and Compliance Officer. The company is also progressively building AI-augmented capabilities across its biometrics functions, with each workflow designed to meet GxP validation requirements before deployment into client delivery.

The ZenQMS implementation follows a period of early growth for Acrosian, including multiple client engagements and continued expansion of its team. The company is headquartered in Princeton, New Jersey, with operations supporting clients globally.

For more information about Acrosian, visit acrosian.com.

About Acrosian

Acrosian LLC is a biometrics contract research organization (CRO) providing clinical data management, biostatistics, statistical programming, and medical writing services to the pharmaceutical, biotechnology, and medical device industries. Founded in 2026 by the leadership team behind one of the industry’s largest independent biometrics CROs, Acrosian combines decades of operational experience with AI-augmented workflows built and validated to GxP requirements before deployment. The company is headquartered in Princeton, New Jersey.

For more information, visit: www.acrosian.com. 

About ZenQMS

ZenQMS provides a powerful, AI-enabled, and easy-to-use electronic Quality Management System (eQMS) designed for GxP-regulated organizations. The fully validated, cloud-based platform streamlines document control, training, audits, supplier management, CAPAs, deviations, and more. With unmatched customer support and a commitment to continuous innovation, ZenQMS helps Quality teams stay stress-free, audit-ready, and laser-focused on compliance over chaos. Learn more at www.zenqms.com.

Media Contact

Don F. McLean, +1-734-716-4182

donald.mclean@acrosian.com 

Built for AI, not retrofitted for AI.

PRINCETON, N.J. (July 22, 2026) — Acrosian LLC today announced its launch as a next-generation biometrics CRO purpose-built for the AI era. Founded by Benjamin Jackson, Soumitra Chowdhury, MBA, and Vladimir Mats, Ph.D., Acrosian reunites the leadership team that previously built one of the world’s largest independent biometrics CROs, with operations spanning three continents, before its acquisition.

Rather than adapting legacy infrastructure to artificial intelligence, the founders chose to build again from the ground up.

Acrosian provides integrated clinical data management, biostatistics, statistical programming, and medical writing services for pharmaceutical, biotechnology, and medical device companies, combining proven operational execution with AI-augmented workflows designed to meet GxP validation requirements before deployment.

“After 18 years of building our previous company, we reached a simple conclusion: rebuilding for the AI era would ultimately be more powerful than retrofitting a legacy organization,” said Soumitra Chowdhury, Co-Founder and Chief Executive Officer. “Large organizations inevitably accumulate processes, systems, and assumptions that make fundamental change difficult. We chose a clean architecture instead—designed for the era we’re entering, not the one we’re leaving.”

Acrosian’s executive leadership includes:

• Benjamin Jackson, Co-Founder and Chairman
• Soumitra Chowdhury, MBA, Co-Founder and Chief Executive Officer
• Vladimir Mats, Ph.D., Co-Founder and Chief Commercial Officer
• Yurii Kartashov, Ph.D., Chief Research & Development Officer
• Aparna (Tanya) Chowdhury, CISA, CDPSE, MIT CSO, Chief Audit and Compliance Officer

“Sponsors are not betting on a new team,” said Vladimir Mats, Ph.D., Co-Founder and Chief Commercial Officer. “They’re working with professionals who have already built and scaled a global biometrics organization. Our clients receive the same scientific rigor, operational discipline, and delivery standards they have trusted for years—now built on an entirely new technological foundation.”

Building AI That Sponsors Can Trust

While much of the industry focuses on AI capabilities, Acrosian’s strategy begins with AI governance.

Every AI-augmented workflow is developed within a unified GxP validation framework before becoming part of client delivery. Human accountability, validation, auditability, security, and documented oversight are built into the firm’s quality system as requirements for every implementation, under a governance framework led by the firm’s Chief Audit and Compliance Officer. Every client deliverable remains under qualified human responsibility, while sponsors receive complete transparency regarding which AI capabilities are currently operational and which remain under active development.

“The industry doesn’t need more AI claims,” said Yurii Kartashov, Ph.D., Chief Research & Development Officer. “It needs confidence in how AI is implemented. We believe sponsors deserve complete transparency—not only about what AI can do today, but also about what it cannot yet do. Trust is built through validation, governance, and honesty.”

This philosophy reflects Acrosian’s broader belief that the future of biometrics will not be defined by replacing experts with artificial intelligence, but by enabling experienced professionals to deliver faster, more consistently, and with greater quality through carefully governed AI augmentation.

Acrosian is actively engaging sponsors ranging from emerging biotechnology companies to global pharmaceutical organizations, providing support from individual biometrics functions through fully integrated biometrics delivery.

For additional information, visit www.acrosian.com.

About Acrosian

Acrosian LLC is a biometrics contract research organization providing clinical data management, biostatistics, statistical programming, and medical writing services to the pharmaceutical, biotechnology, and medical device industries. Founded in 2026 by the leadership team behind one of the industry’s largest independent biometrics CROs, Acrosian combines decades of operational experience with AI-augmented workflows built and validated to GxP requirements before deployment. The company is headquartered in Princeton, New Jersey.

For more information, visit: www.acrosian.com.

Media Contact

Don F. McLean

+1-734-716-4182

donald.mclean@acrosian.com

###